PGNX News and Press, Progenics Pharmaceuticals Inc. From 04/24/19

NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an analysis of an ongoing investigator-initiated st...

NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at...

NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that two abstracts featuring data from the Company’s ...

I have been hesitant about buying into Progenics Pharmaceuticals ( PGNX ) due to my insufficient knowledge about the advancements of radiopharmaceuticals in the oncology arena. Perhaps it is all the hype of immuno-oncology and the rise of gene therapy that caused me to believe that radiopharma...

Progenics Pharmaceuticals, Inc. (PGNX) Q4 2018 Earnings Conference Call March 14, 2019 08:30 AM ET Company Participants Melissa Downs - Associate Director, Investor Relations Mark Baker - Chief Executive Officer Bryce Tenbarge - Senior Vice President of Commercial Pat Fabbio -...

Progenics Pharmaceuticals ( PGNX ) Q4 results : Revenues: $3.2M (-17.9%). More news on: Progenics Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Progenics Pharmaceuticals (NASDAQ: PGNX ): Q4 GAAP EPS of -$0.17 misses by $0.04 . More news on: Progenics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

AZEDRA ® (iobenguane I 131) U.S. Commercial Launch – 14 Treatment Requests from Patients Have Been Received and Scheduling for those Patients is Underway; 8 Centers Throughout the U.S. are Ready to Treat Patients Advancing Lifecycle Initiatives for AZEDRA in Additional MIBG-...

NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has asserte...

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety data from a pooled analysis of all available clinica...